HRP20161717T1 - Nalmefen za smanjenje konzumacije alkohola u specifičnim ciljnim populacijama - Google Patents
Nalmefen za smanjenje konzumacije alkohola u specifičnim ciljnim populacijama Download PDFInfo
- Publication number
- HRP20161717T1 HRP20161717T1 HRP20161717TT HRP20161717T HRP20161717T1 HR P20161717 T1 HRP20161717 T1 HR P20161717T1 HR P20161717T T HRP20161717T T HR P20161717TT HR P20161717 T HRP20161717 T HR P20161717T HR P20161717 T1 HRP20161717 T1 HR P20161717T1
- Authority
- HR
- Croatia
- Prior art keywords
- nalmefene
- alcohol
- longer
- use according
- patient
- Prior art date
Links
- WJBLNOPPDWQMCH-MBPVOVBZSA-N Nalmefene Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=C)O)CC1)O)CC1CC1 WJBLNOPPDWQMCH-MBPVOVBZSA-N 0.000 title claims 25
- 229960005297 nalmefene Drugs 0.000 title claims 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 title claims 12
- 235000019441 ethanol Nutrition 0.000 claims 13
- 230000035622 drinking Effects 0.000 claims 3
- 238000009223 counseling Methods 0.000 claims 2
- 230000002354 daily effect Effects 0.000 claims 2
- 230000003203 everyday effect Effects 0.000 claims 2
- 208000007848 Alcoholism Diseases 0.000 claims 1
- 241000995051 Brenda Species 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 201000007930 alcohol dependence Diseases 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- NSNHWTBQMQIDCF-UHFFFAOYSA-N dihydrate;hydrochloride Chemical compound O.O.Cl NSNHWTBQMQIDCF-UHFFFAOYSA-N 0.000 claims 1
- 238000012423 maintenance Methods 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Neurology (AREA)
- Addiction (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
Claims (12)
1. Nalmefen za uporabu u liječenju ovisnosti o alkoholu u bolesnika koji je ovisan o alkoholu, gdje navedena uporaba smanjuje konzumaciju alkohola u tog bolesnika; pri čemu taj bolesnik ovisan o alkoholu
i) ima DRL (razina rizika pijenja, engl. drinking risk level) koji odgovara konzumaciji >60 g/dan čistog alkohola za muškarce i >40 g/dan čistog alkohola za žene; gdje je taj DRL procijenjen računanjem srednje dnevne konzumacije alkohola u g/dan kroz određeno vrijeme prije procjene, gdje je to vrijeme 1 tjedan ili dulje, kao 2 tjedna ili dulje, kao 3 tjedna ili dulje, kao 4 tjedna ili dulje, kao 1 mjesec ili dulje, kao 2 mjeseca ili dulje, kao 3 mjeseca ili dulje, kao 4 mjeseca ili dulje, kao 5 mjeseci ili dulje, kao 6 mjeseci ili dulje, kao oko 1 godine; i
ii) održava DRL koji odgovara konzumaciji >60 g/dan čistog alkohola za muškarce i >40 g/dan čistog alkohola za žene nakon perioda promatranja od 1-2 tjedna, kao oko 2 tjedna nakon početne procjene;
gdje se taj DRL održavanja procjenjuje računanjem srednje dnevne konzumacije alkohola u g/dan kroz navedeni period promatranja; i gdje se nalmefen daje u terapijski učinkovitoj količini; i gdje se nalmefen daje po potrebi, kao svaki dan kada bolesnik osjeti da postoji rizik da pije alkohol, poželjno 1-2 sata prije očekivanog vremena pijenja.
2. Nalmefen za uporabu prema zahtjevu 1, gdje ta uporaba obuhvaća sljedeće korake;
a) identifikaciju bolesnika koji je ovisan o alkoholu prema zahtjevu 1 i) i ii), gdje je taj bolesnik identificiran prije početka liječenja nalmefenom; i
b) primjenu terapijski učinkovite količine nalmefena bolesniku koji je identificiran u koraku a), gdje se nalmefen daje po potrebi, kao svaki dan kada bolesnik osjeti da postoji rizik da pije alkohol, poželjno 1-2 sata prije očekivanog vremena pijenja.
3. Nalmefen za uporabu prema bilo kojem od zahtjeva 1-2, gdje navedeni bolesnik prolazi savjetovanje s fokusom na poboljšanje pridržavanja terapije i smanjenje konzumacije alkohola.
4. Nalmefen za uporabu prema zahtjevu 3, gdje se to savjetovanje provodi prema BRENDA modelu.
5. Nalmefen za uporabu prema bilo kojem od zahtjeva 1-4, gdje se nalmefen koristi za vrijeme liječenja od 6 -12 mjeseci, kao 6 mjeseci.
6. Nalmefen za uporabu prema bilo kojem od zahtjeva 1-5, gdje bolesnik ima 12 ili više godina, kao 14 ili više godina, kao 16 ili više godina, kao 18 ili više godina.
7. Nalmefen za uporabu prema bilo kojem od zahtjeva 1-6, gdje je količina nalmefena 10-20 mg kao 10 mg, 11 mg, 12 mg, 13 mg, 14 mg, 15 mg, 16 mg, 17 mg, 18 mg, 19 mg ili 20 mg.
8. Nalmefen za uporabu prema zahtjevu 7, gdje je količina nalmefena 18 mg.
9. Nalmefen za uporabu prema bilo kojem od zahtjeva 1-8, gdje se nalmefen primjenjuje u obliku farmaceutski prikladne kisele adicijske soli.
10. Nalmefen za uporabu prema zahtjevu 9, gdje se nalmefen primjenjuje u obliku hidroklorid dihidrata.
11. Nalmefen za uporabu prema bilo kojem od zahtjeva 1-10, gdje se nalmefen primjenjuje u oralnom obliku doze kao što su tablete ili kapsule.
12. Nalmefen za uporabu prema bilo kojem od zahtjeva 1-11, gdje se nalmefen primjenjuje u kombinaciji s dodatnom djelatnom tvari.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261664804P | 2012-06-27 | 2012-06-27 | |
| US201261721539P | 2012-11-02 | 2012-11-02 | |
| US201261736740P | 2012-12-13 | 2012-12-13 | |
| US201361788810P | 2013-03-15 | 2013-03-15 | |
| PCT/EP2013/063461 WO2014001427A1 (en) | 2012-06-27 | 2013-06-27 | Nalmefene for reduction of alcohol consumption in specific target populations |
| EP13732471.1A EP2866808B1 (en) | 2012-06-27 | 2013-06-27 | Nalmefene for reduction of alcohol consumption in specific target populations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20161717T1 true HRP20161717T1 (hr) | 2017-02-10 |
Family
ID=48703496
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20230762TT HRP20230762T8 (hr) | 2012-06-27 | 2013-06-27 | Nalmefen za smanjenje konzumacije alkohola u specifičnim ciljnim populacijama |
| HRP20161717TT HRP20161717T1 (hr) | 2012-06-27 | 2016-12-14 | Nalmefen za smanjenje konzumacije alkohola u specifičnim ciljnim populacijama |
| HRP20180363TT HRP20180363T1 (hr) | 2012-06-27 | 2018-02-28 | Nalmefen, namijenjen smanjivanju potrošnje alkohola kod specifičnih ciljanih populacija |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20230762TT HRP20230762T8 (hr) | 2012-06-27 | 2013-06-27 | Nalmefen za smanjenje konzumacije alkohola u specifičnim ciljnim populacijama |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20180363TT HRP20180363T1 (hr) | 2012-06-27 | 2018-02-28 | Nalmefen, namijenjen smanjivanju potrošnje alkohola kod specifičnih ciljanih populacija |
Country Status (35)
| Country | Link |
|---|---|
| US (4) | US20140005216A1 (hr) |
| EP (4) | EP3138564B1 (hr) |
| JP (3) | JP6258933B2 (hr) |
| KR (1) | KR20150023396A (hr) |
| CN (1) | CN104411313A (hr) |
| AU (1) | AU2013283281B2 (hr) |
| BR (1) | BR112014032555A2 (hr) |
| CA (1) | CA2874703C (hr) |
| CL (1) | CL2014003484A1 (hr) |
| CO (1) | CO7160087A2 (hr) |
| CY (3) | CY1118579T1 (hr) |
| DK (3) | DK2866808T3 (hr) |
| EA (1) | EA029908B1 (hr) |
| ES (3) | ES2950492T3 (hr) |
| FI (1) | FI3345604T3 (hr) |
| HK (2) | HK1208185A1 (hr) |
| HR (3) | HRP20230762T8 (hr) |
| HU (3) | HUE063313T2 (hr) |
| IL (1) | IL236035B (hr) |
| LT (3) | LT3138564T (hr) |
| ME (2) | ME03030B (hr) |
| MX (1) | MX371373B (hr) |
| MY (1) | MY166914A (hr) |
| NZ (1) | NZ702191A (hr) |
| PH (1) | PH12014502798A1 (hr) |
| PL (3) | PL3138564T3 (hr) |
| PT (3) | PT3345604T (hr) |
| RS (2) | RS55456B1 (hr) |
| RU (1) | RU2665373C2 (hr) |
| SG (1) | SG11201408704WA (hr) |
| SI (3) | SI3138564T1 (hr) |
| SM (1) | SMT201600471B (hr) |
| UA (1) | UA114199C2 (hr) |
| WO (1) | WO2014001427A1 (hr) |
| ZA (1) | ZA201409525B (hr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140005216A1 (en) | 2012-06-27 | 2014-01-02 | H. Lundbeck A/S | Nalmefene for reduction of alcohol consumption in specific target populations |
| WO2014170353A1 (en) * | 2013-04-17 | 2014-10-23 | H. Lundbeck A/S | Nalmefene for treatment of patients with sleep disorder |
| CN106456634A (zh) | 2014-04-22 | 2017-02-22 | 大塚制药株式会社 | 布雷帕唑和纳美芬的组合及其用于治疗物质有关的病症的用途 |
| US20170071590A1 (en) * | 2015-09-10 | 2017-03-16 | Suture Armor Llc | Suture anchor |
| KR20190122431A (ko) | 2018-04-20 | 2019-10-30 | 삼성전자주식회사 | 반도체 메모리 소자 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3814768A (en) | 1971-11-26 | 1974-06-04 | Lewenstein E | 6-methylene-6-desoxy dihydro morphine and codeine derivatives and pharmaceutically acceptable salts |
| US4535157A (en) | 1983-11-01 | 1985-08-13 | Key Pharmaceuticals, Inc. | Process for making 6-desoxy-6-methylenenaloxone and 6-desoxy-6-methylenenaltrexone |
| US5086058A (en) * | 1990-06-04 | 1992-02-04 | Alko Ltd. | Method for treating alcoholism with nalmefene |
| HUP0401022A3 (en) * | 2001-08-14 | 2006-11-28 | Biotie Therapies Corp | Method for the preparation of pharmaceutical compositions containing opioid antagonist for treating alcoholism or alcohol abuse |
| UA102128C2 (en) * | 2008-12-05 | 2013-06-10 | Х. Луннбек А/С | Nalmefene hydrochloride dihydrate |
| SI2435439T1 (sl) | 2009-05-25 | 2016-06-30 | H. Lundbeck A/S | Priprava nalmefen hidroklorida iz naltreksona |
| MX2013005009A (es) | 2010-11-05 | 2013-08-01 | Lundbeck & Co As H | Metodo para la elaboracion de naltrexona. |
| RU2552290C1 (ru) | 2011-03-31 | 2015-06-10 | Ак Кимя Итхалат-Ихрацат Ве Санайии А.С. | Соединения опиоидных антагонистов и их применение при лечении склеродермии |
| US20140005216A1 (en) | 2012-06-27 | 2014-01-02 | H. Lundbeck A/S | Nalmefene for reduction of alcohol consumption in specific target populations |
-
2013
- 2013-06-26 US US13/928,317 patent/US20140005216A1/en not_active Abandoned
- 2013-06-26 US US13/928,332 patent/US20140005217A1/en not_active Abandoned
- 2013-06-27 CN CN201380034056.2A patent/CN104411313A/zh active Pending
- 2013-06-27 EP EP16187426.8A patent/EP3138564B1/en not_active Revoked
- 2013-06-27 PL PL16187426T patent/PL3138564T3/pl unknown
- 2013-06-27 SI SI201330973T patent/SI3138564T1/en unknown
- 2013-06-27 EP EP23163177.1A patent/EP4223296A3/en active Pending
- 2013-06-27 HU HUE17206034A patent/HUE063313T2/hu unknown
- 2013-06-27 ME MEP-2018-68A patent/ME03030B/me unknown
- 2013-06-27 LT LTEP16187426.8T patent/LT3138564T/lt unknown
- 2013-06-27 UA UAA201500199A patent/UA114199C2/uk unknown
- 2013-06-27 MY MYPI2014003570A patent/MY166914A/en unknown
- 2013-06-27 LT LTEP17206034.5T patent/LT3345604T/lt unknown
- 2013-06-27 EA EA201492152A patent/EA029908B1/ru not_active IP Right Cessation
- 2013-06-27 DK DK13732471.1T patent/DK2866808T3/en active
- 2013-06-27 ES ES17206034T patent/ES2950492T3/es active Active
- 2013-06-27 JP JP2015519085A patent/JP6258933B2/ja active Active
- 2013-06-27 BR BR112014032555A patent/BR112014032555A2/pt not_active Application Discontinuation
- 2013-06-27 RS RS20161173A patent/RS55456B1/sr unknown
- 2013-06-27 SI SI201330449A patent/SI2866808T1/sl unknown
- 2013-06-27 DK DK17206034.5T patent/DK3345604T3/da active
- 2013-06-27 PT PT172060345T patent/PT3345604T/pt unknown
- 2013-06-27 HR HRP20230762TT patent/HRP20230762T8/hr unknown
- 2013-06-27 EP EP13732471.1A patent/EP2866808B1/en not_active Revoked
- 2013-06-27 HU HUE16187426A patent/HUE036272T2/hu unknown
- 2013-06-27 ES ES16187426.8T patent/ES2663532T3/es active Active
- 2013-06-27 MX MX2014015488A patent/MX371373B/es active IP Right Grant
- 2013-06-27 PT PT161874268T patent/PT3138564T/pt unknown
- 2013-06-27 SG SG11201408704WA patent/SG11201408704WA/en unknown
- 2013-06-27 PL PL13732471T patent/PL2866808T3/pl unknown
- 2013-06-27 CA CA2874703A patent/CA2874703C/en active Active
- 2013-06-27 HU HUE13732471A patent/HUE031110T2/en unknown
- 2013-06-27 NZ NZ702191A patent/NZ702191A/en not_active IP Right Cessation
- 2013-06-27 WO PCT/EP2013/063461 patent/WO2014001427A1/en active Application Filing
- 2013-06-27 ES ES13732471.1T patent/ES2609122T3/es active Active
- 2013-06-27 AU AU2013283281A patent/AU2013283281B2/en not_active Ceased
- 2013-06-27 FI FIEP17206034.5T patent/FI3345604T3/fi active
- 2013-06-27 SI SI201332054T patent/SI3345604T1/sl unknown
- 2013-06-27 PL PL17206034.5T patent/PL3345604T3/pl unknown
- 2013-06-27 KR KR1020147035322A patent/KR20150023396A/ko active IP Right Grant
- 2013-06-27 RS RS20180359A patent/RS57046B1/sr unknown
- 2013-06-27 EP EP17206034.5A patent/EP3345604B1/en active Active
- 2013-06-27 RU RU2014151156A patent/RU2665373C2/ru active
- 2013-06-27 LT LTEP13732471.1T patent/LT2866808T/lt unknown
- 2013-06-27 PT PT137324711T patent/PT2866808T/pt unknown
- 2013-06-27 DK DK16187426.8T patent/DK3138564T3/en active
- 2013-06-27 ME MEP-2016-286A patent/ME02587B/me unknown
-
2014
- 2014-12-02 IL IL236035A patent/IL236035B/en active IP Right Grant
- 2014-12-15 PH PH12014502798A patent/PH12014502798A1/en unknown
- 2014-12-22 CO CO14280546A patent/CO7160087A2/es not_active Application Discontinuation
- 2014-12-22 CL CL2014003484A patent/CL2014003484A1/es unknown
- 2014-12-23 ZA ZA2014/09525A patent/ZA201409525B/en unknown
-
2015
- 2015-09-11 HK HK15108930.9A patent/HK1208185A1/xx not_active IP Right Cessation
-
2016
- 2016-04-07 US US15/093,097 patent/US9642849B2/en active Active
- 2016-12-14 HR HRP20161717TT patent/HRP20161717T1/hr unknown
- 2016-12-27 SM SM201600471T patent/SMT201600471B/it unknown
-
2017
- 2017-01-03 CY CY20171100004T patent/CY1118579T1/el unknown
- 2017-03-22 US US15/466,024 patent/US10034874B2/en active Active
- 2017-09-22 JP JP2017182608A patent/JP2018039810A/ja not_active Withdrawn
-
2018
- 2018-02-28 HR HRP20180363TT patent/HRP20180363T1/hr unknown
- 2018-03-27 CY CY20181100346T patent/CY1120097T1/el unknown
- 2018-11-20 HK HK18114830.5A patent/HK1255683A1/zh unknown
-
2019
- 2019-04-25 JP JP2019083718A patent/JP6857684B2/ja active Active
-
2023
- 2023-07-25 CY CY20231100359T patent/CY1126140T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20161717T1 (hr) | Nalmefen za smanjenje konzumacije alkohola u specifičnim ciljnim populacijama | |
| MX2019013263A (es) | Inhibidores de la recirculacion de acidos biliares para el tratamiento de enfermedades hepaticas colestasicas pediatricas. | |
| HRP20161233T1 (hr) | Neurozaštita u demijelinizirajućim bolestima | |
| JP2013514984A5 (hr) | ||
| HRP20180942T1 (hr) | Liječenje negativnih simptoma shizofrenije s (r)-7-kloro-n-(kinuklidin-3-il)benzo[b]tiofen-2-karboksamidom i njegovim farmaceutski prihvatljivim solima | |
| NZ597237A (en) | Sublingual apomorphine | |
| MA32692B1 (fr) | Procede de liberation d'une composition pharmaceutique a un patient qui en a besoin | |
| JP2018039810A5 (hr) | ||
| MX2012003082A (es) | Composiciones farmaceuticas para reducir la absorcion rapida de la dosis inducida por el alcohol. | |
| AR075735A1 (es) | Composiciones farmaceuticas de liberacion inmediata que comprenden oxicodona y naloxona. uso | |
| NZ625592A (en) | Compositions and methods for the treatment of hepatic diseases and disorders | |
| HRP20240121T1 (hr) | Kontracepcija na bazi drospirenona za pacijenticu s viškom tjelesne težine | |
| PE20081578A1 (es) | Formulacion en polvo de valganciclovir | |
| HRP20230809T1 (hr) | Liječenje alzheimerove bolesti u određenoj populaciji bolesnika | |
| JP2018527305A5 (hr) | ||
| AR063538A1 (es) | Tratamiento de la enfermedad de parkinson | |
| HRP20171678T1 (hr) | Postupci za smanjenje prejedanja ili kompulzivnog jedenja | |
| HRP20130123T1 (hr) | Postupak lijeäśenja bolesti | |
| BR112014014795A2 (pt) | sistema de pélete de multiunidade de liberação imediata | |
| JP2015521647A5 (hr) | ||
| JP2013523628A5 (hr) | ||
| UY33499A (es) | Formulaciones que comprenden particulas finas recubiertas | |
| HRP20230735T1 (hr) | Betahistin, ili njegova farmaceutski prihvatljiva sol, i inhibitor monoamin oksidaze, za uporabu u liječenju ili prevenciji jednog ili više simptoma vrtoglavice kod subjekta | |
| ES2678122T3 (es) | Comprimidos bucales mucoadherentes para el tratamiento del herpes orofacial | |
| HRP20200155T1 (hr) | Farmaceutski pripravak koji obuhvaća drospirenon i kontracepcijski komplet |